EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

E3 ligase Trim35 inhibits LSD1 demethylase activity through K63-linked ubiquitination and enhances anti-tumor immunity in NSCLC

Feiyu Tang, Can Lu, Xiang He, Wei Lin, Bowen Xie, Xing Gao, Yang Peng, Desong Yang, Lunquan Sun, Liang Weng

Cell Reports · 2023-12 · 42 (12) · 113477

DOI: 10.1016/j.celrep.2023.113477 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2023-12. Verfasst von Feiyu Tang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha 410008, China; Key Laboratory of Molecular Radiation Oncology Hunan Provi…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Hunan Province Health Commission, Huxiang Youth Talent Support Program, Health Commission of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeting lysine-specific histone demethylase 1A (LSD1) can improve tumor immunogenicity of poorly immunogenic tumors, such as non-small cell lung cancer (NSCLC), with elevated T cell infiltration and sensitize tumors to anti-PD-1 therapy. However, the lack of reliable biomarkers limits utilization of LSD1 inhibitors in cancer therapy. Here, we identify an E3 ligase, Trim35, as an effective biomarker for high activity of LSD1 to predict prognosis of LSD1-targeted therapy as well as immunotherapy. Mechanistically, Trim35 represses LSD1 demethylase activity by mediating K63 ubiquitination at lysine site 422 of LSD1. Suppressed LSD1 activity facilitates ERGIC1 transcription, followed by autophagy inhibition and IFNGR1 stabilization to activate IFN-γ signaling, leading to increased MHC class I expression and immune surveillance of NSCLC cells. Furthermore, combinational use of an LSD1 inhibitor and anti-PD-1 therapy can significantly eradicate poorly immunogenic lung cancer with low Trim35. These findings strongly suggest that Trim35 is a promising biomarker for prediction of immunotherapy outcome in NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansUbiquitin-Protein LigasesLysineUbiquitinationHistone DemethylasesBiomarkersCell Line, Tumor

Stichwörter der Autor:innen

CP: CancerCP: ImmunologyLSD1NSCLCTrim35immunogenicityubiquitination

Substanzen

Ubiquitin-Protein LigasesLysineHistone DemethylasesBiomarkers

Autor:innen und Institutionen

  • Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha 410008, China; Key Laboratory of Molecular Radiation Oncology Hunan Province, Changsha 410008, China; Hunan International Science and Technolog…
  • Department of Pathology, Xiangya Hospital, Central South University, Changsha 410008, China.
  • Institute of Immunology and School of Medicine, Tsinghua University, Beijing 100084, China.
  • Key Laboratory of Molecular Radiation Oncology Hunan Province, Changsha 410008, China; Department of Stomatology, Xiangya Hospital, Central South University, Changsha 410008, China.
  • Department of Gynecology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
  • Hunan Clinical Medical Research Center of Accurate Diagnosis and Treatment for Esophageal Carcinoma, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Chan…

Förderung

  • Hunan Province Health Commission
  • Huxiang Youth Talent Support Program
  • Health Commission of Hunan Province
  • National Natural Science Foundation of China
  • Natural Science Foundation of Hunan Province

Zitieren

APA

Tang, F., Lu, C., He, X., Lin, W., Xie, B., Gao, X., Peng, Y., Yang, D., Sun, L., & Weng, L. (2023). E3 ligase Trim35 inhibits LSD1 demethylase activity through K63-linked ubiquitination and enhances anti-tumor immunity in NSCLC. Cell Reports, 42(12), 113477. https://doi.org/10.1016/j.celrep.2023.113477

Vancouver

Tang F, Lu C, He X, Lin W, Xie B, Gao X, et al. E3 ligase Trim35 inhibits LSD1 demethylase activity through K63-linked ubiquitination and enhances anti-tumor immunity in NSCLC. Cell Reports. 2023;42(12):113477. doi:10.1016/j.celrep.2023.113477

BibTeX
@article{Tang2023,
  author = {Tang, Feiyu and Lu, Can and He, Xiang and Lin, Wei and Xie, Bowen and Gao, Xing and Peng, Yang and Yang, Desong and Sun, Lunquan and Weng, Liang},
  title = {E3 ligase Trim35 inhibits LSD1 demethylase activity through K63-linked ubiquitination and enhances anti-tumor immunity in NSCLC},
  journal = {Cell Reports},
  year = {2023},
  volume = {42},
  number = {12},
  pages = {113477},
  doi = {10.1016/j.celrep.2023.113477}
}
Kostenlos starten →